Research: OLIVER and WATSON,

Listed in Issue 232

Abstract

OLIVER and WATSON, (1)The Royal Women's Hospital, Grattan St & Flemington Rd, Parkville, VIC, Australia, 3052 conducted a systematic review to determine whether there is evidence that omega-3 polyunsaturated fatty acid supplementation reduces morbidity and mortality and to identify any adverse events associated with supplementation.

Background

Studies suggest that a diet rich in omega-3 essential fatty acids may have beneficial anti-inflammatory effects for chronic conditions such as cystic fibrosis.

Methodology

Search Methods: The authors searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and hand searches of relevant journals and abstract books of conference proceedings. Authors and persons interested in the subject of the review were contacted. Date of last search: 08 July 2013. Selection Criteria: Randomised controlled trials in people with cystic fibrosis comparing omega-3 fatty acid supplements with placebo. Data Collection and Analysis: Two authors independently selected studies for inclusion, extracted data and assessed the risk of bias of the studies.

Results

The searches identified 14 studies; four studies with 91 participants were included. Two studies were judged to be at low risk of bias based on adequate randomisation but this was unclear in the other two studies. Three of the studies adequately blinded patients; however, the risk of bias was unclear in all studies with regards to allocation concealment and selective reporting. Two studies compared omega-3 fatty acids to olive oil for six weeks. One study compared a liquid dietary supplement containing omega-3 fatty acids to one without for six months. One study compared omega-3 fatty acids and omega-6 fatty acids to a control (capsules with customised fatty acid blends) for three months. Only one short-term study (19 participants) comparing omega-3 to placebo reported a significant improvement in lung function and Shwachman score and a reduction in sputum volume in the omega-3 group. Another study (43 participants) demonstrated a significant increase in serum phospholipid essential fatty acid content and a significant drop in the n-6/n-3 fatty acid ratio following omega-3 fatty acid supplementation compared to control. The longer-term study (17 participants) demonstrated a significant increase in essential fatty acid content in neutrophil membranes and a significant decrease in the leukotriene B4 to leukotriene B5 ratio in participants taking omega-3 supplements compared to placebo.

Conclusion

This review found that regular omega-3 supplements may provide some benefits for people with cystic fibrosis with relatively few adverse effects, although evidence is insufficient to draw firm conclusions or recommend routine use of these supplements in people with cystic fibrosis. This review has highlighted the lack of data for many outcomes meaningful to people with or making treatment decisions about cystic fibrosis. A large, long-term, multicentre, randomised controlled study is needed to determine any significant therapeutic effect and to assess the influence of disease severity, dosage and duration of treatment. Future researchers should note the need for additional pancreatic enzymes.

References

Oliver C(1), Watson H. Omega-3 fatty acids for cystic fibrosis.  Cochrane Database Syst Rev. 11:CD002201. doi: 10.1002/14651858.CD002201.pub4. Nov 27 2013. Update of   Cochrane Database Syst Rev (8):CD002201. 2011.

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Berlin to London Bike Ride

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page